What to do if you have toothache after radiotherapy for nasopharyngeal carcinoma

What should I do if I have toothache after radiotherapy for nasopharyngeal carcinoma?

1. For toothache after radiotherapy for nasopharyngeal carcinoma, oral analgesics can be considered for treatment. If the toothache is caused by gum infection, oral anti-infection drugs such as metronidazole can also be taken.

2. It is recommended that you adopt a comprehensive treatment method that combines traditional Chinese medicine syndrome differentiation and treatment with multidisciplinary Western medicine. Nasopharyngeal carcinoma is a very common malignant tumor of the head and neck.

Can I get an injection for nasopharyngeal cancer and a cold?

In daily life, patients with nasopharyngeal cancer are advised to improve their nutrition, keep warm, and try to avoid colds.

There are more cases in the middle and late stages. In addition, about 60% of patients will experience recurrence and metastasis within 3 years after treatment. Therefore, western medicine combined with ginsenoside RH can effectively enhance efficacy and reduce toxicity, shorten the recovery period, and prevent recurrence and metastasis. How long can nasopharyngeal cancer be maintained with injections alone?

Is early nasopharyngeal cancer contagious?

Nasopharyngeal carcinoma is a malignant tumor of the nasopharynx, but it is not an infectious disease and is not contagious. Therefore, it is not contagious. It is recommended to actively cooperate with comprehensive anti-tumor treatment plans such as radiotherapy and chemotherapy after diagnosis to control tumor progression and pay attention to regular check-ups. Nasopharyngeal carcinoma should not be contagious because it is not an infectious disease.

However, nasopharyngeal cancer should be treated with medication or surgery in time, otherwise it will become more and more serious and affect normal life. Nasopharyngeal cancer is a common malignant tumor in my country and the most common malignant tumor in the otolaryngology department, accounting for 78.08% of head and neck malignant tumors.